Suppr超能文献

奥昔布宁和托特罗定用于伊朗女性膀胱过度活动症治疗的一项试验

Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women.

作者信息

Aziminekoo Elham, Ghanbari Zinat, Hashemi Shahrzad, Nemati Maryam, Haghollahi Fedyeh, Shokuhi Nasim

机构信息

Reproductive Health Research Center, Tehran University of Medical Science, Tehran, Iran.

Department of Urogynecology, Emam Hospital, Tehran University of Medical Science, Tehran, Iran.

出版信息

J Family Reprod Health. 2014 Jun;8(2):73-6.

Abstract

OBJECTIVE

To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women.

MATERIALS AND METHODS

One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling cystometry participated in this randomized double-blinded parallel-group by using two kinds of the drugs for 4- week course (2 mg tolterodine twice-daily, or oxybutinin 5 mg, three times a day) in alike packages. We collected data from 3-day FVC before and after the treatment course. The effectiveness of each drug was studied using the paired t-test and improvement after treatment between two groups was compared by independent T-test.

RESULTS

Positive changes in urinary urgency, Frequency and Urge incontinence after treatment in both groups were seen but mean improvements in the all were larger in the patients who treated by oxybutinin especially in terms of urgency and Urge incontinence. Dry mouth was the most common side-effect in two groups. Unlike other studies it was higher in the tolterodine group but the difference was not significant.

CONCLUSION

Four week treatment with oxybutinin was better than tolterodine in improving urgency and urge incontinence but there were not statistically significance between them.

摘要

目的

比较奥昔布宁与托特罗定治疗伊朗女性伴有逼尿肌过度活动(DOA)的膀胱过度活动症(OAB)的疗效及副作用。

材料与方法

100名有OAB临床症状且在膀胱充盈测压中显示逼尿肌不稳定(IDO)的伊朗老年女性参与了这项随机双盲平行组研究,使用两种包装相似的药物进行为期4周的疗程(托特罗定2mg,每日2次;或奥昔布宁5mg,每日3次)。我们收集了治疗疗程前后3天的排尿日记数据。使用配对t检验研究每种药物的有效性,并通过独立t检验比较两组治疗后的改善情况。

结果

两组治疗后尿急、尿频和急迫性尿失禁均有积极变化,但奥昔布宁治疗的患者在所有方面的平均改善更大,尤其是在尿急和急迫性尿失禁方面。口干是两组最常见的副作用。与其他研究不同的是,托特罗定组的口干发生率更高,但差异无统计学意义。

结论

奥昔布宁治疗4周在改善尿急和急迫性尿失禁方面优于托特罗定,但两者之间无统计学差异。

相似文献

3
Which anticholinergic drug for overactive bladder symptoms in adults.
Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2.
4
Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
J Obstet Gynaecol Res. 2015 Jan;41(1):120-6. doi: 10.1111/jog.12483. Epub 2014 Nov 5.
6
Which anticholinergic drug for overactive bladder symptoms in adults.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD005429. doi: 10.1002/14651858.CD005429.
8
Tolterodine: a review of its use in the treatment of overactive bladder.
Drugs Aging. 2001;18(4):277-304. doi: 10.2165/00002512-200118040-00005.

引用本文的文献

1
Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.
Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
2
Otorhinolaryngological adverse effects of urological drugs.
Int Braz J Urol. 2021 Jul-Aug;47(4):747-752. doi: 10.1590/S1677-5538.IBJU.2021.99.06.
3
Updating the evidence on drugs to treat overactive bladder: a systematic review.
Int Urogynecol J. 2019 Oct;30(10):1603-1617. doi: 10.1007/s00192-019-04022-8. Epub 2019 Jul 25.
4
Adverse Events Associated with Nonsurgical Treatments for Urinary Incontinence in Women: a Systematic Review.
J Gen Intern Med. 2019 Aug;34(8):1615-1625. doi: 10.1007/s11606-019-05028-0. Epub 2019 May 6.

本文引用的文献

1
Treatments for overactive bladder: focus on pharmacotherapy.
J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8.
2
Which anticholinergic drug for overactive bladder symptoms in adults.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD005429. doi: 10.1002/14651858.CD005429.
3
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
Drugs. 2004;64(15):1643-56. doi: 10.2165/00003495-200464150-00003.
4
Antimuscarinics for treatment of overactive bladder.
Lancet Neurol. 2004 Jan;3(1):46-53. doi: 10.1016/s1474-4422(03)00622-7.
10
Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
Drugs Aging. 2001;18(7):551-60. doi: 10.2165/00002512-200118070-00007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验